Nasal COVID Vax Shows Promise in Phase 1 Clinical Trial
While the traditional way to administer protection has been to inject vaccines into the bloodstream, many experts called for developing a nasally delivered vaccine as a potentially more-effective approach. Now, encouraging results are in from the first human clinical trial to be conducted in the United States of a nasal COVID vaccine. Findings from the study led by an expert at Cincinnati Children's were published July 4, 2025, in Science Advances.
"A single dose of this vaccine (CVXGA) was well tolerated. It generated a wide spectrum of specific immune responses including mucosal and systemic immune responses. Those who received the highest dose of the vaccine showed significantly lower rates of symptomatic COVID-19 infection," says the study's lead author, Paul Spearman, MD, a long-time leader in vaccine research and vice chair for clinical and translational research and education at Cincinnati Children's.
The vaccine is made by the Georgia-based company CyanVac LLC, which also funded the clinical trial. Based on the promising data generated from this phase 1 trial, two larger clinical studies involving more people are underway (NCT05736835 and NCT06742281).
If these trials also prove successful, the CVXGA vaccine could join four other nasal COVID vaccines approved in other countries: two in China, one in Russia, and another in India.
Why is a nasal vaccine needed?
While the total number of deaths from COVID has declined far from the peak pandemic years, the virus has not disappeared. In fact, 663 Americans died of COVID in the 28 days ended June 15, 2025. Those deaths (which in one month exceeded the combined deaths of the three deadliest plane crashes since 2022) accounted for 67% of the 987 total deaths worldwide reported to the World Health Organization.
India (101 deaths) was the only other nation reporting more than 100 COVID deaths in this timeframe, and its population is more than four times larger than the US. The wealthy Western nation Sweden reported 22 deaths.
Since the pandemic began, the virus has mutated several times. This has required adjusting the vaccine and suggests that annual re-vaccination may be needed to prevent another pandemic. A nasal vaccine could prove both more effective medically and more tolerable for young children and adults who may fear needles.
"There is a need for improved COVID vaccines that offer more complete and durable protection," Spearman says. "A nasal vaccine has the potential to block SARS-CoV-2 at its mucosal entry site and to reduce transmission of the virus to others."
How effective was the nasal vaccine?
The clinical trial included 72 people who received vaccinations, with ages ranging from 12 to 53. A total of 61 participants completed the entire trial. During the period of the trial from September 2021 to May 2023, various waves of SARS-CoV-2 variant infections emerged in the US.
Participants were divided among four groups. One group received a low dose of the vaccine, which served as a control group. The other three higher dose groups included one group of adults that had never been infected or had not been vaccinated recently; a group of adults that had been recently vaccinated with a previous mRNA vaccine; and a group of teens that also had been vaccinated.
Overall, about 25% of recipients reported having a runny nose after the vaccine; 8% reported nausea. None had a fever.
The researchers found evidence that the vaccine was absorbed in the nasal tissues, and that it generated statistically significant antibody responses, as intended.
CVXGA1 produced a combined 51.9% mucosal antibody response rate across the three higher dose groups, compared to just 21.4% in the lower dose group.
The low-dose group (Group 1, enrolled from September 2021 to February 2022) had the highest overall COVID-19 infection rate: 73.3%. The other three groups had infection rates ranging from 11.1% to 22.2%. None of those found to be infected required hospital care.
The results suggest that the vaccine reduced the risk of infection by at least 67% compared to never being vaccinated before. However, definitive proof of efficacy will require larger trials designed specifically for this purpose.
What's next?
By design, a phase 1 clinical trial involves low numbers of participants. However, the results were encouraging enough to recommend moving ahead with larger clinical trials.
The largest of the two ongoing trials (NCT06742281) seeks to enroll up to 10,016 participants by mid-2026 with the study completed by mid-2027.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nasal-covid-vax-shows-promise-in-phase-1-clinical-trial-302497198.html
SOURCE Cincinnati Children's Hospital Medical Center
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Man Adopts a 'Fitness is Fun' Mindset and Loses 85 Pounds Playing This Trendy Game
For Ethan Noblesala, 32, a diagnosis of prediabetes and a blunt prediction from his doctor in November, 2023, motivated him to improve his health. "My doctor told me, 'If you don't change your lifestyle, you're going down a route that's leading to more surgeries, more operations and more medication,'" Noblesala tells TODAY. He says he was at his healthiest during college, but as he built his career as an entrepreneur, he neglected his health and focused on building his businesses. 'As I started that corporate lifestyle, I was slowly gaining weight,' he says. To foster business growth and connections, he was spending a lot of time at happy hours. He was lucky if he slept four hours a night. Uber Eats was the cornerstone of his diet. Exercise or even spending any time outside was practically non-existent. And his habits only got worse during COVID. His weight climbed to 235 pounds, which was a strain on his 5-foot, 6-inch frame. 'Even though I was running a successful business with my co-founder, I decided to take a leave to really focus on what was most important to me — my health,' he says. That attention to his health worked. He lost 85 pounds, and he says he feels 10 years younger. Here's how he did it. Noblesala has a background in finance, so he's motivated by numbers. He honed in on them to make changes, tracking his protein, fiber and calories. He discovered that when he ate mainly protein and fiber-dense meals, he felt satiated even when he was only eating 1,500 calories a day: 'Your body needs nutrition, but I never felt like I was starving myself or restricting myself.' He built on small goals and habit changes: Drinking a glass of water every day: 'I was 85 pounds heavier. I wasn't going to go out and run five miles, or try any of the crazy trends I see online. This was something I could do.' Shopping for groceries and checking the nutrition labels for protein, fiber and calories instead of eating out — and overeating — five times a week. Having a go-to, high-fiber, low-calorie meal that he liked to eat: Shirataki noodles with chicken breast in a low-fat buffalo sauce. Finding healthier swaps for foods he likes, such as Costco chicken nuggets instead of McDonald's: 'I found it exciting to make these new discoveries. It's something I love to do.' Noblesala grew up playing sports and loved how they kept him active while also being a way to connect with others. He'd often ask his friends if they wanted to play basketball, tennis or something else together. 'Through tennis, I discovered pickleball. That was the hook for me in terms of living a healthier and active lifestyle. I've become a pickleball fanatic,' he says. In December 2023, he joined Life Time. 'One thing I appreciate there is the community. I get to play pickleball, my favorite sport. Some people say going to the gym is a chore, but I'm excited to go." "There are endorphins you get from exercising, from being around others and from having that community," he says. "In the past, going to the gym was a solo grind, and I had to force myself to go. Now, it's not a chore. It's part of my lifestyle." Having friends at the gym and at pickleball builds accountability for him, too. 'My friends will say, 'Ethan, I'll see you tomorrow.' And, of course, then I go after work. They're expecting me,' he says. He has also joined some running clubs, such as Pitch & Run, and now he's working toward an ambitious goal — running the New York City marathon in November. He earned the opportunity to participate through his alma mater, Chaminade High School in Long Island. 'I'm nervous for the marathon because I know it's a daunting mental task. I'm focusing on the interval training and the strength training,' he says. Noblesala recognizes now how his lack of sleep was making his health worse: 'Your body needs to recover. I'm averaging six and a half to seven and a half hours of sleep a night now, and I definitely feel it when I don't get seven hours of sleep.' He's also careful about balancing his workouts with rest. He finds fitness data so valuable that he wears an Apple watch, a Whoop tracker and an Oura ring. After a day where he ran seven miles and played two hours of pickleball, he saw that his Whoop told him to take it lighter the next day. 'You can make these informed decisions with technology. It was harder to do this 10 years ago,' he says. Now that Noblesala is 85 pounds lighter and his life is centered around healthy living, he has no intention of returning to his old habits. In fact, it inspired Ethan's new company WeFit Labs, which is a gamified social fitness app designed to help motivate people to move together. If you're looking for a fitness community, join our Start TODAY walking club on Facebook and connect live with members and experts during coaching calls on the Start TODAY app! This article was originally published on
Yahoo
2 hours ago
- Yahoo
CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry
CORAL SPRINGS, FL / / July 4, 2025 / CELFULL, a biotechnology company with over 25 years of expertise in anti-aging science, has announced a major breakthrough in longevity innovation: the global launch of Celfavor® NADH Microcapsules, a patented delivery system that resolves the century-long challenge of NADH instability. Journal papers related to NADH This revolutionary technology-protected by seven international invention patents across the U.S., China, Japan, Canada, and South Korea-delivers unprecedented improvements in stability, bioavailability, and targeted delivery, marking a new era in anti-aging therapeutics known as the "Microcapsule Age." To accelerate research across the globe, CELFULL has also launched its Global Research Sharing Program, offering free access to the Celfavor® NADH raw material to scientific institutions worldwide. Celfavor®NADH The only effective NADH - Celfavor ® NADH "The discovery of the therapeutic effect of stabilized NADH is more important to humankind than the discovery of antibiotics." noted Nobel Laureate Sir John Eccles, underscoring the importance of this innovation. NADH stands for "nicotinamide adenine dinucleotide (NAD) + hydrogen (H), often dubbed the "King of Anti-Aging Molecules," plays a central role in mitochondrial energy production, antioxidant defense, and the activation of longevity proteins. However, its inherent instability-sensitive to heat, light, oxygen, and stomach acid-has severely limited its clinical applications. Conventional NADH degrades by over 70% in one month at room temperature and must be stored at -20°C, making practical use difficult. 7 patents have been certified CELFULL's research team, led by its AI-powered Multi-Target Anti-Aging Institute, spent over a decade solving this problem. The result: Celfavor® NADH Microcapsules, a proprietary technology featuring 250-350μm microcapsules that protect NADH with a multi-core soluble shell made from food-grade materials. In stability tests simulating harsh conditions (40°C / 75% RH), traditional NADH retained only 3.5% of its activity after six months. By contrast, Celfavor® NADH maintained 98.3% activity-demonstrating over 6x shelf-life extension, even without refrigeration or light shielding. The stability of Celfavor® NADH microspheres The Celfavor® NADH Microcapsule system delivers innovation across four dimensions: 1. Enhanced Stability: Microcapsules shield NADH from air, moisture, light, and stomach acid, preserving its full potency in gastrointestinal conditions for up to 4 hours. 2. Targeted Release: Using AI-optimized wall material, the system enables "zero release in the stomach and sustained release in the intestine." Simulated intestinal studies show 24-hour continuous release, extending absorption time by 5-8x. 3. Superior Bioavailability: In human trials, a daily dose of 40mg led to a 98% increase in blood NAD⁺ levels, a 3.2x improvement over regular NADH. Performance also surpassed other NAD⁺ precursors like NMN and NR. 4. Formulation Flexibility: Unlike unstable NADH, Celfavor® NADH can be safely co-formulated with vitamins, coenzymes, or peptides in single or multi-ingredient capsules. Celfavor ® NADH microsphere advanced technology surpasses others Celfavor® NADH Microcapsules have been granted seven invention patents and passed all 12 safety evaluations, including cytotoxicity and long-term toxicity tests. It is currently the only NADH raw material globally to pass full-spectrum safety certification. The only globally certified raw material for toxicology and safety experiments "We are not just creating better products-we are building a platform for the future of longevity," said Dr. Juliane Hitzel, CEO of CELFULL. "With this microcapsule technology, we're launching new delivery systems for vitamins, peptides, and more. And by sharing our raw materials with global researchers, we're fostering a collaborative ecosystem that accelerates anti-aging science." From solving the NADH stability problem to advancing intelligent delivery systems, CELFULL's innovation signals a major milestone in human longevity science. As the Celfavor® NADH Microcapsule technology rolls out globally, the anti-aging industry enters a new chapter-one defined by precision, efficiency, and collaboration. For business cooperation or research partnerships, please contact:maggie@ | Email: maggie@ SOURCE: CELFULL View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Washington Post
2 hours ago
- Washington Post
Asking Eric: After ugly comments, brother invites himself to party
Dear Eric: Nearly eight months ago, my 81-year-old brother lashed out saying hateful and hurtful things about our youngest sister. At the time, I suspected he was drunk and probably frustrated from the repeated episodes of our sister's illnesses and problems, some of which have been caused by her own serious eating disorder, depression and occasional binge drinking.
